Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (231-240 of 388) with videos related to

Pageof 39
Sort By:
Clinical Drug Investigation|June 13, 2022
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell CarcinomaDaniel M Geynisman, Mauricio Burotto, Camillo Porta, et al.
Clinical Genitourinary Cancer|October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell CarcinomaCora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|May 4, 2022
Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapySara De Biasi, Annalisa Guida, Domenico Lo Tartaro, et al.
The Oncologist|September 20, 2022
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
BJU International|May 6, 2019
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancerMarzia Del Re, Stefania Crucitta, Andrea Sbrana, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
European Urology|February 3, 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta, Emiliano Calvo, Miguel A Climent, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
European Urology|September 12, 2012
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)Sergio Bracarda, Camillo Porta, Corrado Boni, et al.
Pageof 39

Showing results (231-240 of 388) with videos related to

Sort By:
Pageof 39
Clinical Drug Investigation|June 13, 2022
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell CarcinomaDaniel M Geynisman, Mauricio Burotto, Camillo Porta, et al.
Clinical Genitourinary Cancer|October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell CarcinomaCora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|May 4, 2022
Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapySara De Biasi, Annalisa Guida, Domenico Lo Tartaro, et al.
The Oncologist|September 20, 2022
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
BJU International|May 6, 2019
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancerMarzia Del Re, Stefania Crucitta, Andrea Sbrana, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
European Urology|February 3, 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta, Emiliano Calvo, Miguel A Climent, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
European Urology|September 12, 2012
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)Sergio Bracarda, Camillo Porta, Corrado Boni, et al.
Pageof 39